Deneen Vojta, MD
Deneen is a visionary physician executive grounded in clinical medicine, scientific research, and new business development. She thrives on finding opportunities and modernizing how we access, pay for, and experience the healthcare system. Deneen is persistent in pursuing good ideas, passionate about engaging with teams in discovery and execution. She is valued for her direct style, natural curiosity and intuition, and unfaltering energy as she brings clarity to goals and makes strategy actionable. She is an Entrepreneur in Residence at BioAdvance where she sits on the investment committee. Most recently, Deneen was the EVP for Research and Development for UnitedHealth Group where for 16 years, she led the ideation, successful execution, and profitable exit of multiple businesses, leveraging data and general-purpose technologies into transformative applications and care delivery models. Previously, Deneen was the Founder and CEO of MYnetico, a digital health platform, that was acquired by UHG in 2006. Earlier, she was the Chief Medical Officer of ARIA Health Care System and of Health Partners of Philadelphia. She began her career serving as a resident in Pediatrics, fellow in Hematology & Oncology, and attending physician at CHOP.
Deneen currently serves on the governance boards of Hikma Pharmaceuticals (LSE: HIK), Sensei Biotherapeutics (NASDAQ: SNSE) and Canary Medical as well as the advisory board of The Center for Health Incentives & Behavioral Economics at Penn Medicine. In 2022 she was a Modern Healthcare’s Top Innovator; in 2014, an Emmy® Award winner; and in 2013, a CES® Innovation Design & Engineering Innovation Honoree. Deneen received her MD from the Temple University School of Medicine and BS in Neuroscience from the University of Pittsburgh.